New drug trial aims to tame rare autoimmune disease flares
NCT ID NCT04520451
Summary
This study tested whether adding a new oral drug called rilzabrutinib to standard steroid treatment could better control disease activity in adults with IgG4-related disease, a rare condition where the immune system attacks the body's own tissues. About 27 participants were split into two groups: one received rilzabrutinib plus steroids, and the other received steroids alone. The main goal was to see if the combination could prevent disease flares better than steroids by themselves.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN G4 RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 12403
Vancouver, V6K 2V8, Canada
-
Investigational Site Number 25013
Marseille, France
-
Investigational Site Number 38016
Milan, Italy
-
Investigational Site Number 72415
Barcelona, Spain
-
Investigational Site Number 84016
Boston, Massachusetts, 02114, United States
-
Investigational Site Number 84018
Detroit, Michigan, 48202, United States
-
Investigational Site Number 84019
Stanford, California, 94305, United States
-
Investigational Site Number 84030
New York, New York, 10021, United States
-
Investigational Site Number 84036
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.